The biotech and pharmaceutical industry is in the middle of a twenty-year-long transformation of commercial models. The shift from pipelines to orphan and newer modalities (and fewer mass-market blockbusters) combined with advances in analytics, cloud platforms, machine learning and artificial intelligence is driving that multidecade transformation, with COVID accelerating change.
In this webinar, ZS emerging biopharma and launch experts discuss:
- Practices that emerging and smaller biotech and pharma can implement now
- What to infer about the commercial model of 2030 and beyond
- How to balance efficiency and effectiveness
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
